Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Cardiovascular Outcomes# EXSCEL Trial (Exenatide)# The EXSCEL trial (Holman et al., NEJM 2017) enrolled 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease) and followed them for a median of 3.2 years: Primary MACE endpoint : HR 0.91 (95% CI 0.83-1.00), p=0.06 for superiority Met non-inferiority but narrowly missed superiority (p=0.06) All-cause mortality was reduced by 14% (HR 0.86, p=0.016) in a secondary analysis EXSCEL confirmed cardiovascular safety but did not prove cardiovascular benefit -- a critical distinction
I didnt use a lip liner, and even the darkest shade went on beautifully
Track Progress Beyond the Scale Focusing only on the scale creates frustration because weight loss is not linear
Fu T, Xu Z, Liu L, Guo Q, Wu H, Liang X, et al
It is a multifunctional molecule which is naturally produced by your body
People with Graves disease are at a greater risk of developing a vitamin B12 deficiency
US$ 24.15
US$ 24.91
US$ 23.48
US$ 21.87
US$ 28.12
US$ 28.35
US$ 24.34
US$ 26.94
US$ 25.20
